Frontiers in Genetics (May 2023)

A new perspective on Alzheimer’s disease: m6A modification

  • Lei Xia,
  • Lei Xia,
  • Lei Xia,
  • Fan Zhang,
  • Fan Zhang,
  • Fan Zhang,
  • Fan Zhang,
  • Fan Zhang,
  • Yulu Li,
  • Yulu Li,
  • Yulu Li,
  • Yuemi Mo,
  • Yuemi Mo,
  • Yuemi Mo,
  • Lingqiu Zhang,
  • Lingqiu Zhang,
  • Lingqiu Zhang,
  • Qianhua Li,
  • Qianhua Li,
  • Qianhua Li,
  • Minghuang Luo,
  • Minghuang Luo,
  • Minghuang Luo,
  • Xiaotao Hou,
  • Xiaotao Hou,
  • Xiaotao Hou,
  • Xiaotao Hou,
  • Zhengcai Du,
  • Zhengcai Du,
  • Zhengcai Du,
  • Zhengcai Du,
  • Jiagang Deng,
  • Jiagang Deng,
  • Jiagang Deng,
  • Jiagang Deng,
  • Erwei Hao,
  • Erwei Hao,
  • Erwei Hao,
  • Erwei Hao

DOI
https://doi.org/10.3389/fgene.2023.1166831
Journal volume & issue
Vol. 14

Abstract

Read online

As a neurodegenerative disease, Alzheimer’s disease (AD) is characterized by synaptic loss, extracellular plaques of amyloid accumulation, hyperphosphorylation of tau, and neuroinflammation. Various biological processes are affected by epitranscriptomic modifications, which regulate the metabolism of mRNA in cells and regulate the expression of genes. In response to changes in m6A modification levels, the nervous system becomes dysfunctional and plays a significant role in the development of Alzheimer’s disease. As a result of recent research, this paper reviews advances in the understanding of the regulatory mechanisms of m6A modification in the occurrence and development of AD. In addition, the article discusses recent research techniques related to animal models of m6A and AD. Furthermore, it discusses the possibility of studying the pathogenesis of AD at the level of the epitranscriptome, identifying early diagnostic markers, and screening for effective treatment options.

Keywords